ROSEN, A LEADING LAW FIRM, Reminds MEI Pharma, Inc. Investors of Important October 9 Deadline in Securities Class Action

NEW YORK, Sept. 28, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (the “Class Period”), of the important October 9, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for MEI Pharma investors under the federal securities laws.

Rosen Law Firm, P.A. Logo
Rosen Law Firm, P.A. Logo

To join the MEI Pharma class action, go to http://www.rosenlegal.com/cases-register-1919.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) MEI Pharma overstated Pracinostat’s potential efficacy as an acute myeloid leukemia (“AML”), treatment for the target population; (2) consequently, the Phase 3 Pracinostat Trial was unlikely

Read More

ROSEN, A TOP RANKED LAW FIRM, Reminds Wrap Technologies, Inc. Investors of Important Deadline in Securities Class Action First Filed by the Firm

NEW YORK, Sept. 28, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Wrap Technologies, Inc. between July 31, 2020 and September 23, 2020, inclusive (the “Class Period”) of the important November 23, 2020 lead plaintiff deadline in the case commenced by the firm. The lawsuit seeks to recover damages for Wrap investors under the federal securities laws.

Rosen Law Firm, P.A. Logo
Rosen Law Firm, P.A. Logo

To join the Wrap class action, go to http://www.rosenlegal.com/cases-register-1953.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the Company had concealed the results of the LAPD BolaWrap pilot program, which demonstrated that the BolaWrap was ineffective, expensive, and sparingly used in the field; and (2)

Read More